Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

12.26
-0.1700-1.37%
Post-market: 12.15-0.1100-0.90%18:51 EST
Volume:77.32K
Turnover:957.03K
Market Cap:76.55M
PE:-10.77
High:12.59
Open:12.45
Low:12.19
Close:12.43
52wk High:18.38
52wk Low:4.63
Shares:6.24M
Float Shares:4.51M
Volume Ratio:0.52
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1389
EPS(LYR):-1.1526
ROE:-44.80%
ROA:-29.14%
PB:0.80
PE(LYR):-10.64

Loading ...

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

GlobeNewswire
·
Feb 04

Tenax Therapeutics Updates Chief Medical Officer Agreement

TIPRANKS
·
Jan 10

Tenax Therapeutics Prorates CMO Salary for Reduced Work Schedule

Reuters
·
Jan 10

BRIEF-Tenax Therapeutics Level Trial On Track To Complete Enrollment In H1 2026

Reuters
·
Dec 17, 2025

Tenax Therapeutics Inc - Level Trial on Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026

THOMSON REUTERS
·
Dec 17, 2025

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

GlobeNewswire
·
Dec 17, 2025

Tenax Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Dec 17, 2025

Tenax Therapeutics Chief Medical Officer Stuart Rich Reports Acquisition of Common Shares

Reuters
·
Dec 11, 2025

Tenax Therapeutics Chief Medical Officer Stuart Rich Reports Acquisition of Common Shares

Reuters
·
Dec 06, 2025

Tenax Therapeutics Executives to Present at Major Healthcare Investor Conferences

Reuters
·
Nov 25, 2025

CEO Makes Bold Move with Major Stock Purchase in Tenax Therapeutics!

TIPRANKS
·
Nov 21, 2025

Director’s Bold Move: A Significant Investment in Tenax Therapeutics!

TIPRANKS
·
Nov 20, 2025

Tenax Therapeutics Director June Sherie Almenoff Reports Acquisition of Common Shares

Reuters
·
Nov 20, 2025

Tenax Therapeutics Q3 Net Income USD -15.804 Million

Reuters
·
Nov 20, 2025

Tenax Therapeutics Inc : Leerink Partners Raises Target Price to $26 From $20

THOMSON REUTERS
·
Nov 14, 2025

Tenax Therapeutics to hold a conference call

TIPRANKS
·
Nov 13, 2025

Tenax Therapeutics Reports Increased R&D Expenses Amid Clinical Trials

TIPRANKS
·
Nov 13, 2025

Tenax Therapeutics Q3 EPS $(0.40) Misses $(0.32) Estimate

Benzinga
·
Nov 13, 2025

Tenax Therapeutics posts Q3 net loss of $15.8 million

Reuters
·
Nov 13, 2025

BRIEF-Tenax Therapeutics Q3 Net Income USD -15.804 Million

Reuters
·
Nov 13, 2025